<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329950</url>
  </required_header>
  <id_info>
    <org_study_id>CDX1140-01</org_study_id>
    <secondary_id>Keynote-A23</secondary_id>
    <nct_id>NCT03329950</nct_id>
  </id_info>
  <brief_title>A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody),&#xD;
      either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to&#xD;
      further evaluate its tolerability and efficacy in expansion cohorts once the MTD is&#xD;
      determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability&#xD;
      and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2),&#xD;
      pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer.&#xD;
&#xD;
      Eligible patients that enroll to the dose-escalation portion of the study will be assigned to&#xD;
      one of several dose levels of CDX-1140. The dose-escalation part of the study will test the&#xD;
      safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or&#xD;
      chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion&#xD;
      portions of the study.&#xD;
&#xD;
      All patients enrolled in the study will be closely monitored to determine if there is a&#xD;
      response to the treatment as well as for any side effects that may occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0</measure>
    <time_frame>From first dose through 30 days after last dose</time_frame>
    <description>The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years.</time_frame>
    <description>The percentage of patients who achieved a confirmed complete response or partial response by evaluation criteria in solid tumors for immune-based therapeutics (iRECIST; for solid tumor patients) and the lymphoma response to immunomodulatory therapy criteria (LYRIC; for lymphoma patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years</time_frame>
    <description>The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death (up to approximately 1-3 years)</time_frame>
    <description>The interval from which measurement criteria are first met for CR or PR until the first date that progressive disease is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 1-3 years)</time_frame>
    <description>The time from start of study drug to time of progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from start of study drug to death from any cause (up to approximately 1-3 years)</time_frame>
    <description>The time from start of study drug to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity evaluation</measure>
    <time_frame>Prior to each dose of study treatment and at treatment discontinuation, up to approximately 1-3 years</time_frame>
    <description>Serum samples will be obtained for assessment of human anti-CDX-1140 and anti-CDX-301 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>Prior to each study treatment, multiple timepoints after each study treatment, and at treatment discontinuation up to approximately 1-3 years</time_frame>
    <description>CDX-1140 and CDX-301 concentrations will be measured</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Bladder Urothelial Carcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Hepatic Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Other Solid Tumors</condition>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Indolent B-cell Lymphomas</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Waldenstrom's Disease</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Mucosa Associated Lymphoid Tissue</condition>
  <condition>Small Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>CDX-1140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-1140</intervention_name>
    <description>CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.</description>
    <arm_group_label>CDX-1140</arm_group_label>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-301</intervention_name>
    <description>CDX-301 will be injected once a day for five days before Cycles 1 and 2.</description>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered every 3 weeks.</description>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.</description>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular),&#xD;
             bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast,&#xD;
             colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary&#xD;
             peritoneal carcinoma, head and neck, and cholangiocarcinoma. Additional tumor types&#xD;
             (except primary CNS tumors) may be enrolled after discussion with, and approval from,&#xD;
             the medical monitor.&#xD;
&#xD;
          2. Must have received all standard of care therapies (approved or unapproved) as deemed&#xD;
             appropriate by the treating physician. Patients who refuse standard therapy are&#xD;
             excluded from the study.&#xD;
&#xD;
          3. If of childbearing potential (male or female), agrees to practice an effective form of&#xD;
             contraception during study treatment and for at least 3 months following last&#xD;
             treatment&#xD;
&#xD;
          4. Willingness to undergo a pre-treatment and on-treatment biopsy, if required.&#xD;
&#xD;
        Additional Inclusion Criteria for Part 1:&#xD;
&#xD;
          1. Advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, or indolent&#xD;
             B-cell lymphoma are also eligible.&#xD;
&#xD;
          2. Lymphoma patients must have received ≥ 1 prior systemic therapy&#xD;
&#xD;
        Additional Inclusion Criteria for Part 3:&#xD;
&#xD;
          1. Patients must have documented progression while receiving anti-PD-1 or anti-PD-L1&#xD;
             based regimens for FDA approved indications&#xD;
&#xD;
          2. Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen&#xD;
&#xD;
        Additional Inclusion Criteria for Part 4:&#xD;
&#xD;
        1. Patients must have metastatic pancreatic adenocarcinoma, and have not received previous&#xD;
        treatment in a metastatic setting&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History of severe hypersensitivity reactions to other monoclonal antibodies.&#xD;
&#xD;
          2. Previous treatment with any anti-CD40 antibody or with FLT3L.&#xD;
&#xD;
          3. Inadequate washout period from prior therapy as defined in the Protocol.&#xD;
&#xD;
          4. Major surgery within 4 weeks prior to study treatment.&#xD;
&#xD;
          5. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within&#xD;
             2 weeks prior to study treatment.&#xD;
&#xD;
          6. Other prior malignancy, except for adequately treated basal or squamous cell skin&#xD;
             cancer or in situ cancers. For all other cancers, the patient must be disease-free for&#xD;
             at least 3 years to be allowed to enroll.&#xD;
&#xD;
          7. Active, untreated central nervous system metastases.&#xD;
&#xD;
          8. Active autoimmune disease or documented history of autoimmune disease.&#xD;
&#xD;
          9. History of (non-infectious) pneumonitis or has current pneumonitis.&#xD;
&#xD;
         10. Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or&#xD;
             Hepatitis C.&#xD;
&#xD;
        Additional Exclusion Criteria for lymphoma patients in Part 1:&#xD;
&#xD;
          1. Prior allogenic stem cell transplantation&#xD;
&#xD;
          2. Patients who have received autologous stem cell transplant ≤ 12 weeks prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
        There are additional criteria your study doctor will review with you to confirm your&#xD;
        eligibility for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Insititute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
      <phone>480-323-1350</phone>
      <email>Michael.Gordon@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Dan Mocan</last_name>
      <phone>480-323-3661</phone>
      <email>dmocan@honorhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <phone>404-303-3355</phone>
      <email>clinicaltrials@northside.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jenkins</last_name>
      <phone>706-721-1206</phone>
      <email>kjenkins@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Loveday</last_name>
      <phone>706-721-5095</phone>
      <email>ploveday@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vamsi Kota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West, PC dba Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Pierce</last_name>
      <phone>402-691-6972</phone>
      <email>gpierce@nebraskacancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Delbeau, MSN, AGCNS-BC, RN</last_name>
      <phone>212-824-7811</phone>
      <email>Daniela.Delbeau@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Bhardwaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Khalil, MD</last_name>
      <phone>646-888-4384</phone>
      <email>khalild@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Danny Khalil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Dessecker</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>213</phone_ext>
      <email>bdessecker@gabrailcancercenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher, RN</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.Fisher@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Tara Foote, RN</last_name>
      <phone>503-215-7192</phone>
      <email>Tara.Foote@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center at the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagan Loburak</last_name>
      <phone>215-614-7677</phone>
      <email>Sagan.Loburak@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Louie</last_name>
      <phone>215-220-9668</phone>
      <email>Jennifer.Louie2@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark O'Hara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital (RIH) The Miriam Hospital (TMH)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kuhlman, MBA, BS, BA</last_name>
      <phone>401-444-5014</phone>
      <email>RKuhlman@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Adam Olszewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Shephard, MD</last_name>
      <email>mailto:mshephard@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Maen Abdelrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX-1140</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>GI Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Celldex</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibody</keyword>
  <keyword>CD40</keyword>
  <keyword>CD-40</keyword>
  <keyword>Flt3l</keyword>
  <keyword>CDX-301</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Bile duct cancer</keyword>
  <keyword>TNBC</keyword>
  <keyword>RCC</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Dendritic cell</keyword>
  <keyword>Keynote A-23</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>CD40L</keyword>
  <keyword>CD40 Ligand</keyword>
  <keyword>Pancreas cancer</keyword>
  <keyword>Metastatic pancreas cancer</keyword>
  <keyword>Unresectable pancreas cancer</keyword>
  <keyword>Stage IV pancreas cancer</keyword>
  <keyword>Squamous cell cancer lung</keyword>
  <keyword>Non-squamous cell cancer lung</keyword>
  <keyword>Metastatic lung cancer</keyword>
  <keyword>Stage IV lung cancer</keyword>
  <keyword>Squamous cell cancer of head and neck</keyword>
  <keyword>Stage IV cancer of head and neck</keyword>
  <keyword>Throat cancer</keyword>
  <keyword>Oropharyngeal cancer</keyword>
  <keyword>Laryngeal cancer</keyword>
  <keyword>Oral cancer</keyword>
  <keyword>FLT3 Ligand</keyword>
  <keyword>fms-like tyrosine kinase 3 ligand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

